Tim Clackson, Theseus CEO

The Ari­ad vets de­vel­op­ing next-gen TKIs are head­ing back to Nas­daq — and Or­biMed stands to reap the most

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

By June 2018, the dust on Take­da’s $5.2 bil­lion buy­out of Ari­ad On­col­o­gy had long set­tled. The biotech’s on­col­o­gy and hema­tol­ogy port­fo­lio was in the hands of the phar­ma’s com­mer­cial team; ex­ecs moved on­to new gigs; and on the pipeline front, Take­da was steer­ing a slate of can­di­dates through tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.